Evotec Management

Management criteria checks 2/4

Evotec's CEO is Mario Polywka, appointed in Jan 2024, has a tenure of less than a year. directly owns 0.007% of the company’s shares, worth $117.87K. The average tenure of the management team and the board of directors is 1.6 years and 4.8 years respectively.

Key information

Mario Polywka

Chief executive officer

€60.0k

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	0.007%
Management average tenure	1.6yrs
Board average tenure	4.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Mario Polywka's remuneration changed compared to Evotec's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-€84m
Sep 30 2023	n/a	n/a	-€95m
Jun 30 2023	n/a	n/a	-€103m
Mar 31 2023	n/a	n/a	-€117m
Dec 31 2022	€60k	n/a	-€176m
Sep 30 2022	n/a	n/a	-€180m
Jun 30 2022	n/a	n/a	€2m
Mar 31 2022	n/a	n/a	€90m
Dec 31 2021	€56k	n/a	€216m
Sep 30 2021	n/a	n/a	€247m
Jun 30 2021	n/a	n/a	€112m
Mar 31 2021	n/a	n/a	€42m
Dec 31 2020	€50k	n/a	€6m
Sep 30 2020	n/a	n/a	€14m
Jun 30 2020	n/a	n/a	€35m
Mar 31 2020	n/a	n/a	€42m
Dec 31 2019	€27k	n/a	€38m
Sep 30 2019	n/a	n/a	€61m
Jun 30 2019	n/a	n/a	€77m
Mar 31 2019	n/a	n/a	€94m
Dec 31 2018	€846k	€316k	€84m
Sep 30 2018	n/a	n/a	€63m
Jun 30 2018	n/a	n/a	€31m
Mar 31 2018	n/a	n/a	€20m
Dec 31 2017	€816k	€320k	€23m

Compensation vs Market: Mario's total compensation ($USD64.18K) is below average for companies of similar size in the US market ($USD5.66M).

Compensation vs Earnings: Mario's compensation has increased whilst the company is unprofitable.

CEO

Mario Polywka (60 yo)

less than a year

Tenure

€60,000

Compensation

Dr. Mario Polywka, Ph D., D.Phil., serves as Director at Blacksmith Medicines, Inc. He was Independent Member of the Supervisory Board at Evotec SE since June 19, 2019 and also serves as its Member of Mana...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Mario Polywka	Interim CEO	less than a year	€60.00k	0.0067% € 117.9k
Werner Lanthaler	Member of Management Board	less than a year	€2.52m	0.87% € 15.2m
Cord Dohrmann	Chief Scientific Officer & Member of Management Board	13.6yrs	€1.40m	0.11% € 1.9m
Craig Johnstone	COO & Member of Management Board	5.3yrs	€2.11m	0.011% € 199.1k
Matthias Evers	Chief Business Officer & Member of Management Board	2.3yrs	€1.54m	no data
Laetitia Rouxel	CFO & Member of Management Board	less than a year	no data	0.029% € 510.4k
Anja Bosler	Principal Accounting Officer and Senior Vice President of Group Accounting	no data	no data	no data
Volker Braun	Executive VP and Head of Global Investor Relations & ESG	no data	no data	no data
Christian Dargel	EVP Global Head of Legal & Compliance	no data	no data	no data
Gabriele Hansen	Senior VP & Head of Global Corporate Communications & Marketing	no data	no data	no data
Ian Hunneyball	Senior Vice President of Programme Management & Clinical Operations	no data	€116.00k	no data
David Hallet	Executive Vice President	no data	no data	no data

1.6yrs

Average Tenure

55yo

Average Age

Experienced Management: EVOT.F's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Mario Polywka	Interim CEO	4.8yrs	€60.00k	0.0067% € 117.9k
Roland Sackers	Independent Vice Chairperson of the Supervisory Board	4.8yrs	€95.00k	no data
Iris Low-Friedrich	Independent Chairperson of the Supervisory Board	9.8yrs	€150.00k	no data
Elaine Sullivan	Independent Member of Supervisory Board	8.8yrs	€65.30k	no data
Camilla Languille	Member of the Supervisory Board	1.8yrs	€31.60k	no data
Constanze Ulmer-Eilfort	Independent Member of Supervisory Board	2.8yrs	€73.20k	no data

4.8yrs

Average Tenure

60yo

Average Age

Experienced Board: EVOT.F's board of directors are considered experienced (4.8 years average tenure).

Evotec Management

Management criteria checks 2/4

Key information

Recent management updates

Evotec SE Welcomes Aurélie Dalbiez as Chief People Officer, Effective 15 June 2024

Evotec SE Announces CEO Transition

Evotec SE, Annual General Meeting, Jun 20, 2023

Evotec SE Appoints Laetitia Rouxel as Member of the Management Board, Effective 01 April 2023

Evotec Se Appoints Camilla Macapili Languille as New Member of Supervisory Board

Evotec Appoints Cord Dohrmann to the German Council of Science and Humanities

Recent updates

Evotec SE Provides Earnings Guidance for the Year 2024

Evotec SE Welcomes Aurélie Dalbiez as Chief People Officer, Effective 15 June 2024

Evotec SE to Report Fiscal Year 2023 Results on Apr 24, 2024

Evotec SE to Report Q1, 2024 Results on May 22, 2024

Evotec SE Announces CEO Transition

Evotec SE Announces Zhejiang Jingxin Pharmaceutical Co., Ltd Receives Approval for EVT201 in China

Evotec SE to Report Nine Months, 2023 Results on Nov 08, 2023

Evotec SE (XTRA:EVT) acquired remaining 50% stake in NephTera Gmbh from Vifor (International) AG for €1.65 million.

Evotec SE Provides Revenue Guidance for the Full Year 2023

Evotec SE Revises Earnings Guidance for the Fiscal Year 2023

Evotec SE, Annual General Meeting, Jun 20, 2023

Evotec SE Appoints Laetitia Rouxel as Member of the Management Board, Effective 01 April 2023

Evotec SE Reaffirms Earnings Guidance for the Full Year 2022

Evotec Launches PanOmics Data Analysis Platform PanHunter At Bio-IT World

Evotec SE (XTRA:EVT) agreed to acquire Central Glass Germany GmbH from Central Glass Co., Ltd. (TSE:4044) for €1.

Evotec SE Revises Revenue Guidance for the Full Year 2022

Evotec SE (XTRA:EVT) completed the acquisition of Rigenerand S.R.L. from Xyence Capital SGR and others.

Evotec Se Appoints Camilla Macapili Languille as New Member of Supervisory Board

Evotec SE (XTRA:EVT) agreed to acquire Rigenerand S.R.L. for €25 million.

Evotec SE Confirms Revenue Guidance for 2022

Evotec Se Provides Revenue Guidance for 2022

Evotec SE Announces That the Company Has Been Informed by Bayer About A Decision to Discontinue the Development of the Investigational P2X3 Receptor Antagonist Eliapixant

Evotec SE to Report Q1, 2022 Results on May 11, 2022

Evotec Receives € 7.5 Million Grant for Development of Covid-19 Therapeutic from German Federal Ministry of Education and Research

Evotec SE Provides Revenue Guidance for the Full Year of 2021

Evotec SE (XTRA:EVT) acquired Campus Levi-Montalcini from GlaxoSmithKline plc (LSE:GSK).

Evotec SE Reports Revenue Guidance for Revenue for the Full-Year 2021

Evotec SE Launches 'beLAB1407' to Accelerate Translational Research from the UK's Academic Life Science Ecosystem in Collaboration with Bristol Myers Squibb

Evotec SE Provides Earnings Guidance for the Year 2021

Chinook Therapeutics, Inc. and Evotec SE Announce Strategic Collaboration to Discover and Develop Novel Precision Medicines for Chronic Kidney Diseases

Evotec and Related Sciences Enter Integrated Drug Discovery and Development Partnership

Evotec SE Enters into Multi-Year Partnership with the Medical Center Hamburg-Eppendorf

Evotec Appoints Cord Dohrmann to the German Council of Science and Humanities

Evotec Starts Clinical Development of Chikungunya Antibody together with NIAID and Leading Academic Research Organisation

Evotec SE to Report Q3, 2021 Results on Nov 11, 2021

Evotec SE Receives USD 6 Million Payment from Bristol Myers Squibb Company

Evotec SE Partners with Alloy Therapeutics to Expand Its Antibody Discovery Platform

Evotec and Rappta Therapeutics Enter Discovery and Development Partnership Focused on Oncology Target

Evotec SE announced that it expects to receive €249.999996 million in funding from Mubadala Investment Company PJSC, Novo Holdings A/S

Evotec Achieves Milestone in Its Neurodegeneration Collaboration with Bristol Myers Squibb

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age